H. Lundbeck (WBAG:LUN) - Stock Price, News & Analysis

LUN Stock Overview

LUN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 69.1% below our estimate of its fair value

Earnings are forecast to grow 26.72% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Profit margins (6.8%) are lower than last year (12.1%)

Large one-off items impacting financial results

H. Lundbeck A/S Competitors

Organon

NYSE:OGN

US$4.6b

Haisco Pharmaceutical Group

SZSE:002653

CN¥28.0b

Hikma Pharmaceuticals

LSE:HIK

UK£4.0b

Aspen Pharmacare Holdings

JSE:APN

R96.6b

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	kr.23.20
52 Week High	kr.26.99
52 Week Low	kr.19.77
Beta	0
1 Month Change	0%
3 Month Change	5.89%
1 Year Change	-8.84%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-19.14%

Recent updates

Shareholder Returns

	LUN	AT Pharmaceuticals	AT Market
7D	0%	-1.3%	-0.3%
1Y	-8.8%	4.4%	2.4%

Return vs Industry: LUN underperformed the Austrian Pharmaceuticals industry which returned 1% over the past year.

Return vs Market: LUN underperformed the Austrian Market which returned 3.3% over the past year.

Price Volatility

Is LUN's price volatile compared to industry and market?
LUN volatility
LUN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	3.4%
10% most volatile stocks in AT Market	5.4%
10% least volatile stocks in AT Market	1.6%

Stable Share Price: LUN has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LUN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1915	5,353	Deborah Dunsire	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
LUN fundamental statistics
Market cap	€4.77b
Earnings (TTM)	€148.98m
Revenue (TTM)	€2.20b

31.1x

P/E Ratio

2.1x

P/S Ratio

Is LUN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUN income statement (TTM)
Revenue	kr.16.40b
Cost of Revenue	kr.3.51b
Gross Profit	kr.12.89b
Other Expenses	kr.11.78b
Earnings	kr.1.11b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 17, 2022

Earnings per share (EPS)	1.12
Gross Margin	78.59%
Net Profit Margin	6.76%
Debt/Equity Ratio	32.2%

How did LUN perform over the long term?

See historical performance and comparison

LUN Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

NYSE:OGN

US$4.6b

SZSE:002653

CN¥28.0b

LSE:HIK

UK£4.0b

JSE:APN

R96.6b

Price History & Performance

Recent News & Updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

First quarter 2022 earnings released: EPS: kr.2.07 (vs kr.3.13 in 1Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Less than half of directors are independent

Upcoming dividend of kr.2.00 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

Third quarter 2021 earnings released: EPS kr.1.62 (vs kr.2.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr.1.90 (vs kr.2.93 in 2Q 2020)

First quarter 2021 earnings released: EPS kr.3.13 (vs kr.0.76 in 1Q 2020)

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

Independent Director has left the company

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Full year 2020 earnings released: EPS kr.7.95 (vs kr.13.42 in FY 2019)

New 90-day high: €33.92

Revenue misses expectations

New 90-day high: €28.98

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020